LFG316 + intravenous immunoglobulin

LFG316 + intravenous immunoglobulin is a combination of two agents: **LFG316 (tesidolumab)**, a human IgG1 monoclonal antibody targeting complement protein C5, and **intravenous immunoglobulin (IVIG)**, a polyclonal immunoglobulin product purified from human plasma. LFG316 acts by binding to complement component C5, inhibiting its cleavage and thereby blocking formation of pro-inflammatory C5a and membrane attack complex C5b-9; this leads to inhibition of terminal complement–mediated inflammation and cell destruction[1][3]. IVIG is a pooled preparation of human immunoglobulin G used as broad immunomodulation, anti-inflammatory, and anti-autoimmune agent, with multiple mechanisms including Fc receptor blockade, modulation of complement activation, and neutralization of pathogenic autoantibodies. The combination is not a standard marketed product but may be used in clinical trial or compassionate settings targeting severe complement-mediated disorders. The individual components have primarily been studied in conditions such as geographic atrophy, non-infectious uveitis, and paroxysmal nocturnal hemoglobinuria (LFG316)[1][3], and as established supportive therapy in various autoimmune and immunodeficiency syndromes (IVIG). The combined use would theoretically target both terminal complement activation (LFG316) and provide broad immunomodulation (IVIG).

Other names

tesidolumab + intravenous immunoglobulin